Forty five patients with cystic fibrosis (age 5-15 years) were assessed for heart-lung trans figure) . Most deaths were due to respiratory disease and therefore many of these patients may be eligible for heart-lung transplantation. Heart-lung transplantation was first successfully performed in adults with pulmonary vascular disease in 19812 and later in those with cystic fibrosis.3 Experience of heart-lung transplantation in children is limited, but an early report has shown encouraging results.4
walk (540 m v 854 m), and minimal oxygen saturation (81-5% v 92%). Psychological evaluation demonstrated a 55% incidence of individual and a 50% incidence of family morbidity.
Of the 26 patients accepted onto the active waiting list, 11 have been transplanted (mean waiting time months), 10 have died within a mean of [3] [4] [5] [6] [7] months of acceptance, and five remain on the active list (mean 5-6 months). Despite the improving prognosis in cystic fibrosis' there is still an appreciable mortality in the young child and adolescent in the United Kingdom, with a total of 41 deaths between the ages of 1-14 years reported in 1988 (figure). Most deaths were due to respiratory disease and therefore many of these patients may be eligible for heart-lung transplantation. Heart-lung transplantation was first successfully performed in adults with pulmonary vascular disease in 19812 and later in those with cystic fibrosis.3 Experience of heart-lung transplantation in children is limited, but an early report has shown encouraging results. 4 Since paediatric referrals for heart-lung transplantation were accepted at our institutes, by far the largest single group has been children with cystic fibrosis (45 of the 64). For Heart-lung transplantation for cysticfibrosis. Complete dental examination, including radiography, was undertaken to exclude occult infection and any dental caries found was dealt with during or soon after admission.
As well as a formal 12 lead electrocardiography and echocardiography, a 24 hour electrocardiographic tape was taken to assess the suitability of the heart as a possible donor organ (the domino procedure). 5 Both patient and family underwent extensive psychosocial evaluation by a psychiatrist (BL) and psychologist (ES). This was complemented by informal assessment throughout the admission by the transplant liaison sister (MG).
The child's psychological functioning was determined by his/her mental state (mood, anxiety), coping mechanism, and general adjustment and attitude to illness. Questionnaires and a semistructured psychiatric interview were utilised. Three levels of functioning were determined: level 1 indicated normal functioning, level 2 moderate dysfunction, and level 3 severe dysfunction. 6 A similar rating of functioning of the family as a whole was obtained by observing family interactions, parental subsystem, communication, and problem solving during a clinical interview.
On completion of the inpatient assessment, a combined decision meeting was convened with the family. For younger children (less than 10 years), this was usually confined to the parents, but older children were included if they wished. Patients were either accepted on to an active transplant waiting list indicating they were eligible for transplantation from that time, a provisional waiting list indicating that they were not severely enough affected but would be reassessed at a later date, or not accepted having been assessed as too well.
Children accepted on to the active list underwent further preparation by the ward sister, the transplant liaison sister, the play specialist and/ or school teacher. Logistical arrangements for patient transfer at time of transplantation, including the issuing of a long range radio pager, were organised by the coordinator (IM).
Comparison Child (n=22) 10 7 5 Family (n=22) 11 8 3 Whitehead, Helms, Goodwin, Martin, Lask, Serrano, Scott, Smyth, Higenbottam, Wallwork, Elliott, Leval
Only one patient had clinical evidence of severe hepatic involvement associated with portal hypertension. None of the patients assessed showed abnormal renal function. Mean (SD) plasma creatinine concentration was 49'4 [tmoll. All patients on the active list were negative for cytomegalovirus antibody. This had important implications for donor selection, as we specified cytomegalovirus compatibility in order to avoid the development of life threatening pneumonitis post-transplant. '7 Of the 26 patients accepted on the active waiting list, 11 were transplanted (mean waiting time 3-3 months), 10 died within a mean of [3] [4] [5] [6] [7] months of acceptance, and five remain on the active list (mean 5 6 months). The second part of our selection criteria, namely a severely impaired quality of life, raises further difficulties. Few guidelines are available in the current literature'9 and the whole topic is plagued ty subjective interpretations. By combining both objective clinical measurements and the more subjective quality of life measures, we believe an appropriate decision can be made. Contraindications to heart-lung transplantation are decreasing in number as further experience is gained. For example, patients with previuos thoracotomy, diabetes mellitus, and those on low dose steroid treatment are now accepted. Those with cirrhosis and portal hypertension may also be eligible for heart, lung, and liver transplantation as experience with this technique increases.20 Accordingly, current absolute contraindications may become only relative in the future. We were fortunate in that patients, and/or families, who would be unsuitable for heartlung transplantation due to psychosocial contraindications, tended not to be referred for assessment in the first instance. However, there remains a relatively high incidence of psychological morbidity in those reaching formal assessment as observed in our population. Indentifying the child and/or family with underlying psychological problems (level of functioning 2 and 3) helps to establish a framework for preparation for transplantation and after care. Together with the added burdens of awaiting transplantation and then of transplantation itself,2' it is imperative that a psychosocial support network is mobilised for 'at risk' patients and families.
Dispelling unrealistic expectations and confronting families with the realities of transplantation can be painful, but is an essential part of the assessment. The uncertainties of the waiting period, the immediate postoperative phase, and more importantly the long term issues of rejection, infection, life long drug treatment with its associated side effects, repeated hospitalisation and disruption to the family, must be balanced against the hoped for improved quality of life. The same degree of honesty must be afforded the child, particularly in confronting death, something many parents find difficult to cope with.
At the time of preparation, the total cost of the assessment admission was £1408. This represented 5 4% of the first year's total cost when transplantation was performed. This cost could be greatly reduced if assessment was managed on an outpatient basis, but we feel this approach would be counterproductive for both the patient and the transplant team.
The outcome of those patients undergoing heart-lung transplantation is discussed in the second part of this review.22 The release of endotoxin into the circulation leads to shock and tissue damage through the intermediary of cytokines. The destruction of endotoxin might therefore be expected to be beneficial. Previous trials showing a protective effect have involved the use of polyclonal antisera produced in human volunteers. Monoclonal IgM antibody (HA-lA) is produced from myeloma cell cultures. It is more specific, binding to the lipid A domain of the lipopolysaccharide endotoxin, and its use avoids the need to immunise volunteers and the dangers of using pooled human blood.
The trial was performed at 24 academic medical centres in the United States, Canada, and Europe. All the patients were severely ill with septic shock defined on clinical grounds.
A total of 543 patients entered the trial and were randomly assigned to receive either HA-lA or placebo (human albumin). Two hundred patients proved to have Gram negative bacteraemia on blood culture and the analysis of the trial results is confined to this 200, 105 of whom received HA-lA and 95 placebo.
Overall mortality was reduced from 50% in the placebo group to 30% in the treatment group. Benefit was seen both in those.very severely ill (severe shock and high APACHE score) and in those less severely ill. No serious adverse reactions to the treatment were encountered.
This trial on adults has important implications in paediatrics. Neisseria meningitidis is a potent producer of endotoxin and antibody against lipid A should be effective in meningococcal septicaemia. A multicentre trial of HA-lA in meningococcal septicaemia in children has recently started. The results will be awaited with great interest.
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